COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention group: This study is performed on only one group of patients who all receive hydroxyurea tablets (500 mg three times a day) in addition to the usual COVID-19 treatments according to the n
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory confirmation of Coronavirus disease-19 (COVID-19) virus by reverse transcription- polymerase chain reaction (RT-PCR) Oxygen saturation less than 90% Respiratory rate more than 24 per minute More than 50% involvement of the lung parenchyma on CT scan
Exclusion criteria
Exclusion criteria: White blood cell count less than 2500 million cells per microliter Absolute neutrophil count less than 1000 million cells per microliter Platelet count less than 80,000 cells per microliter More than 50% increase in creatinine compared to the amounts of admission time Pregnancy Active hepatitis B or C infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral blood oxygen saturation. Timepoint: Every other day after starting treatment (up to a week). Method of measurement: Pulseoxymeter.;Hemoglobin F levels. Timepoint: Every other day after starting treatment (up to a week). Method of measurement: Hemoglobin electrophoresis.;Blood cell count. Timepoint: Every other day after starting treatment (up to a week). Method of measurement: Laboratory report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza Keyvanfar
Shahid Beheshti University of Medical Sciences
Outcome results
None listed